Moderna, Inc. (MRNA)
| Market Cap | 103.15B +872.4% |
| Revenue (ttm) | 2.23B -27.6% |
| Net Income | -3.15B |
| EPS | -8.01 |
| Shares Out | 399.24M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,826,059 |
| Open | 235.00 |
| Previous Close | 228.44 |
| Day's Range | 230.21 - 258.72 |
| 52-Week Range | 22.28 - 258.72 |
| Beta | 1.17 |
| Analysts | Hold |
| Price Target | 138.37 (-46.45%) |
| Earnings Date | Nov 6, 2026 |
About MRNA
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provid... [Read more]
Financial Performance
In 2025, Moderna's revenue was $1.94 billion, a decrease of -39.93% compared to the previous year's $3.24 billion. Losses were -$2.82 billion, -20.75% less than in 2024.
Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for MRNA stock is "Hold." The 12-month stock price target is $138.37, which is a decrease of -46.45% from the latest price.
News
These stocks have soared the most today after the Democrats trounced Trump
Stanley Black & Decker's stock was the strongest performer among the S&P 500, while several tech players and associated power providers showed sharp declines.
Moderna advances investigational Bundibugyo ebola vaccine toward Phase 2/3 study
Moderna (MRNA) announced that mRNA-1469, the Company’s investigational mRNA vaccine candidate against Bundibugyo ebolavirus, has been recommended to advance into a Phase 2/3 efficacy study in the Demo...
Moderna announces presentation of data from Phase 1/2 study of mRNA-2808
Moderna (MRNA) announced that initial clinical data from its ongoing Phase 1/2 study of mRNA-2808 have been selected for oral presentation at the 68th American Society of Hematology, ASH, Annual…
Moderna, Merck eye FDA approval for promising cancer vaccine
Moderna co-founder and board chairman Noubar Afeyan discusses the biotech company's melanoma vaccine trial results and efforts to secure FDA approval on 'The Claman Countdown.'
Jobs, Midterm Elections, Apple, Palantir, McDonald's, Moderna, and More to Watch This Week
In another busy earnings week, AMD, Estée Lauder, Qualcomm, Pfizer, and many more will report results. We'll see three readings on jobs this week, as well as data on the manufacturing and services sec...
Moderna's CEO told The Wall Street Journal that his cancer vaccine's data will get better with time, and that no one can easily copy the company's work
Stéphane Bancel defended his melanoma data and argued that rivals can't easily copy the technology.
Moderna Stock (MRNA) Falls 3% as Analysts Question $80 Billion Valuation Despite CEO’s Defense of Cancer Vaccine
Moderna ($MRNA) shares fell 3% in pre-market trading today after Wall Street analysts warned that its Phase 3 melanoma trial results were weaker than mid-stage data and showed higher side…
Moderna Has Its Doubters. CEO Bancel Plans to Answer With a Cancer Shot.
Moderna CEO Stéphane Bancel says the biotech's competitive edge stems from its mRNA platform, likening it to software in Big Tech.
Moderna downgraded to Market Perform from Outperform at William Blair
William Blair downgraded Moderna (MRNA) to Market Perform from Outperform and no price target The firm cites valuation for the downgrade with the stock up 545% year-to-date. Blair sill believes…
Moderna down 3% to $192.90 after William Blair downgrade
06:30 EDT Moderna (MRNA) down 3% to $192.90 after William Blair downgrade
Moderna CEO Sees Cancer Vaccines Working Beyond Melanoma
Moderna CEO Stephane Bancel believes the personalized mRNA cancer vaccine being developed with Merck will work in a variety of tumors. Speaking with Romaine Bostick on "Bloomberg The Close," Bancel al...
Moderna's Rally May Have Run Out of Steam. Here's What to Watch Next
Moderna's stock has taken a big hit that could signal the end of this year's cancer vaccine-driven rally. It may not be too late to play the forces behind its rise.
Data about Merck and Moderna Melanoma Vaccine Leaks Out
Leaked data from Moderna and Merck's highly anticipated melanoma vaccine trial has led to a rare disconnect between doctors, who celebrated the result, and Wall Street, which sold off the stocks. Norm...
The excitement around Moderna's cancer vaccine is cooling. Here's why.
Investors had “incredibly high” expectations around the Phase 3 data for the drugmaker's experimental cancer treatment.
Moderna price target raised to $230 from $167 at Piper Sandler
Piper Sandler raised the firm’s price target on Moderna to $230 from $167 and keeps an Overweight rating on the shares. The firm notes Moderna (MRNA) and partner Merck (MRK)…
Moderna Transcript: Study update
INTerpath-001 found intismeran plus pembrolizumab reduced recurrence or death risk 42% and distant metastasis or death risk 38% versus pembrolizumab alone. RFS benefit was stronger after six months; safety was broadly consistent, while OS follow-up continues.
Moderna Slides: Study update
Moderna has posted slides in relation to its latest quarterly earnings report, which was published on October 24, 2026.
Heard on the Street: Moderna's cancer vaccine passed its first big test this past week. The bigger problem is that its stock is priced as if it has already passed them all.
Even after its latest sharp fall, the drugmaker's stock price assumes wild successes.
To the scientific world, Moderna's cancer vaccine's results proved that a highly personalized, immune-targeting medication can work. To investors, it didn't work well enough.
The company's stock dropped after details of a study raised questions about how widely the treatment would be used.
Moderna’s Cancer Vaccine Earns Praise from Doctors amid Stock Selloff
Biotech company Moderna ($MRNA) saw its shares fall by as much as 25% on Thursday, October 22, despite positive results from a late-stage trial of its personalized cancer vaccine. The…
The real test for Moderna's cancer vaccine isn't about beating Keytruda. It's keeping cancer from coming back in the long term.
The first Phase 3 data for a cancer vaccine has raised questions about whether the potential new treatment is needed.
Moderna leaked data was positive, what's hurting MRNA stock then?
Moderna's (MRNA) leaked cancer-vaccine trial results looked “promising” on the surface, yet the biotech stock came under intense pressure late on Thursday and was weak on Friday morning too, although ...
MRNA Plunges 20% in Two Days: Leak Shows Positive Cancer Vaccine Trial Results
Moderna (MRNA) shares plunged after a partial leak showed results for the company's cancer vaccine trial. As Alison Kosik points out, the results were positive but weren't enough for investors.
Doctors call Moderna, Merck's cancer vaccine data a major advancement — even as stocks fall
Beneath the chaos surrounding Moderna and Merck's latest data on their personalized cancer vaccine, oncologists see something else: an important milestone in melanoma treatment. The companies on Thurs...